Ardelyx (ARDX) | Financial Analysis & Statements
Ardelyx Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
125.2M
Gross Profit
114.4M
91.34%
Operating Income
5.1M
4.07%
Net Income
-407.0K
-0.33%
EPS (Diluted)
$0.00
Balance Sheet Metrics
Total Assets
501.6M
Total Liabilities
334.7M
Shareholders Equity
166.9M
Debt to Equity
2.00
Cash Flow Metrics
Operating Cash Flow
19.4M
Free Cash Flow
20.6M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Ardelyx Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 407.3M | 333.6M | 124.5M | 52.2M | 10.1M |
| Cost of Goods Sold | 39.5M | 50.6M | 17.8M | 4.1M | 1.0M |
| Gross Profit | 367.8M | 283.1M | 106.7M | 48.0M | 9.1M |
| Gross Margin % | 90.3% | 84.8% | 85.7% | 92.1% | 90.1% |
| Operating Expenses | |||||
| Research & Development | 71.5M | 52.3M | 35.5M | 35.2M | 91.1M |
| Selling, General & Administrative | 337.2M | 258.7M | 134.4M | 76.6M | 72.3M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 408.8M | 311.0M | 169.9M | 111.8M | 163.4M |
| Operating Income | -41.0M | -28.0M | -63.3M | -63.8M | -154.3M |
| Operating Margin % | -10.1% | -8.4% | -50.8% | -122.2% | -1,528.6% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 28.4M | 20.1M | 8.9M | 5.1M | 4.5M |
| Other Non-Operating Income | 8.7M | 9.2M | 6.6M | 1.6M | 687.0K |
| Pre-tax Income | -60.6M | -38.9M | -65.5M | -67.2M | -158.2M |
| Income Tax | 969.0K | 266.0K | 547.0K | 8.0K | 4.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -61.6M | -39.1M | -66.1M | -67.2M | -158.2M |
| Net Margin % | -15.1% | -11.7% | -53.1% | -128.9% | -1,566.5% |
| Key Metrics | |||||
| EBITDA | -29.2M | -16.7M | -55.4M | -61.0M | -150.9M |
| EPS (Basic) | $-0.26 | $-0.17 | $-0.30 | $-0.42 | $-1.52 |
| EPS (Diluted) | $-0.26 | $-0.17 | $-0.30 | $-0.42 | $-1.52 |
| Basic Shares Outstanding | 241033750 | 235232927 | 219331253 | 158690083 | 104205645 |
| Diluted Shares Outstanding | 241033750 | 235232927 | 219331253 | 158690083 | 104205645 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Ardelyx Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 68.0M | 64.9M | 21.5M | 96.1M | 72.4M |
| Short-term Investments | 196.7M | 185.2M | 162.8M | 27.8M | 44.3M |
| Accounts Receivable | 71.8M | 57.7M | 22.0M | 7.7M | 502.0K |
| Inventory | 17.7M | 21.2M | 12.4M | 3.3M | 0 |
| Other Current Assets | 13.6M | 11.1M | 8.4M | 5.1M | 7.1M |
| Total Current Assets | 382.3M | 356.5M | 246.1M | 153.6M | 133.6M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 4.8M | 2.4M | 5.6M | 9.3M | 20.2M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 112.3M | 75.4M | 40.6M | 25.9M | 1.2M |
| Total Non-Current Assets | 119.3M | 79.3M | 51.5M | 36.5M | 16.3M |
| Total Assets | 501.6M | 435.8M | 297.6M | 190.1M | 149.9M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 19.2M | 16.0M | 11.1M | 10.9M | 4.3M |
| Short-term Debt | 1.5M | 1.6M | 4.4M | 30.6M | 35.8M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 7.3M | 8.8M | 2.0M | 2.5M | 1.2M |
| Total Current Liabilities | 88.6M | 77.8M | 50.4M | 65.6M | 52.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 206.5M | 151.9M | 51.5M | 5.9M | 9.7M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 246.0M | 184.6M | 80.4M | 26.1M | 14.5M |
| Total Liabilities | 334.7M | 262.5M | 130.8M | 91.7M | 67.3M |
| Equity | |||||
| Common Stock | 24.0K | 24.0K | 23.0K | 20.0K | 13.0K |
| Retained Earnings | -946.9M | -885.3M | -846.2M | -780.1M | -712.9M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 166.9M | 173.3M | 166.8M | 98.3M | 82.6M |
| Key Metrics | |||||
| Total Debt | 208.0M | 153.4M | 56.0M | 36.5M | 45.5M |
| Working Capital | 293.7M | 278.6M | 195.7M | 88.0M | 80.8M |
Balance Sheet Composition
Ardelyx Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -61.6M | -39.1M | -66.1M | -67.2M | -158.2M |
| Depreciation & Amortization | 3.1M | 2.1M | 1.3M | 1.1M | 2.8M |
| Stock-Based Compensation | 49.0M | 37.4M | 13.5M | 10.8M | 12.0M |
| Working Capital Changes | -47.7M | -75.0M | -36.5M | -24.0M | -4.2M |
| Operating Cash Flow | -58.8M | -70.6M | -82.8M | -73.2M | -144.8M |
| Investing Activities | |||||
| Capital Expenditures | -1.5M | -1.0M | -344.0K | 1.7M | -1.9M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -218.9M | -195.2M | -215.2M | -50.3M | -72.7M |
| Investment Sales | 211.5M | 177.9M | 84.3M | 67.0M | 125.6M |
| Investing Cash Flow | -9.0M | -18.3M | -131.2M | 18.4M | 50.9M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 48.7M | 99.5M | 22.4M | 27.0M | 0 |
| Debt Repayment | - | 0 | 0 | -33.0M | -19.4M |
| Financing Cash Flow | 48.7M | 98.5M | 145.1M | 75.1M | 81.6M |
| Free Cash Flow | -44.0M | -45.8M | -90.1M | -70.1M | -154.4M |
| Net Change in Cash | -19.1M | 9.5M | -69.0M | 20.4M | -12.2M |
Cash Flow Trend
Ardelyx Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-22.87
Forward P/E
10.57
Price to Book
8.71
Price to Sales
3.58
PEG Ratio
0.23
Profitability Ratios
Profit Margin
-15.12%
Operating Margin
4.07%
Return on Equity
-36.21%
Return on Assets
-5.46%
Financial Health
Current Ratio
4.32
Debt to Equity
140.06
Beta
0.66
Per Share Data
EPS (TTM)
$-0.26
Book Value per Share
$0.68
Revenue per Share
$1.69
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ARDX | 1.5B | -22.87 | 8.71 | -36.21% | -15.12% | 140.06 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
| Amylyx | 1.9B | 2.54 | 6.31 | -61.59% | 0.00% | 1.95 |
Financial data is updated regularly. All figures are in the company's reporting currency.






